Recombinant human bone morphogenetic protein induces bone formation

Proc Natl Acad Sci U S A. 1990 Mar;87(6):2220-4. doi: 10.1073/pnas.87.6.2220.

Abstract

We have purified and characterized active recombinant human bone morphogenetic protein (BMP) 2A. Implantation of the recombinant protein in rats showed that a single BMP can induce bone formation in vivo. A dose-response and time-course study using the rat ectopic bone formation assay revealed that implantation of 0.5-115 micrograms of partially purified recombinant human BMP-2A resulted in cartilage by day 7 and bone formation by day 14. The time at which bone formation occurred was dependent on the amount of BMP-2A implanted; at high doses bone formation could be observed at 5 days. The cartilage- and bone-inductive activity of the recombinant BMP-2A is histologically indistinguishable from that of bone extracts. Thus, recombinant BMP-2A has therapeutic potential to promote de novo bone formation in humans.

MeSH terms

  • Animals
  • Bone Development / drug effects*
  • Bone Morphogenetic Proteins
  • Bone and Bones / cytology
  • Cartilage / cytology
  • Cartilage / drug effects
  • Cartilage / growth & development*
  • Cell Line
  • Growth Substances / pharmacology*
  • Humans
  • Molecular Weight
  • Proteins / genetics
  • Proteins / isolation & purification
  • Proteins / pharmacology*
  • Rats
  • Recombinant Proteins / isolation & purification
  • Recombinant Proteins / pharmacology

Substances

  • Bone Morphogenetic Proteins
  • Growth Substances
  • Proteins
  • Recombinant Proteins